27 January 2014 by Amany El Gazayerly

EMA Perspective: Post-IMPRES, what is the future of TKI in PH Therapy?

All credit to Amany El Gazayerly, FPVRI, Dr. at Dutch Medicines Evaluation Board, Utrecht | Netherlands

presented at the PVRI/ECCPS joint conference and the 7th PVRI Scientific Workshops and Debates, January 27-31st 2014, in Bad Nauheim, Germany.

 

Additional key-words:  registration,imatinib,IMPRESS,efficacy,

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg